Prevenar

On 21 November 2017, the European Commission withdrew the marketing authorisation for Prevenar (pneumococcal polysaccharide conjugate vaccine (7\-valent, adsorbed)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Pfizer Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. Prevenar was granted marketing authorisation in the EU on 2 February 2001 for immunisation against disease caused by Streptococcus pneumoniae. The marketing authorisation was initially valid for a 5\- year period. It was subsequently renewed for an additional 5\-year period in 2006 and then granted unlimited validity in 2011\. The European Public Assessment Report (EPAR) for Prevenar is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.